Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:KYMR News 9 December 2025 - 4 January 2026

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

Kymera Therapeutics stock extends slide as KYMR closes down 6.5% — what investors watch next

NEW YORK, Jan 4, 2026, 11:20 ET — Market closed Kymera Therapeutics, Inc. (KYMR) shares closed down 6.5% on Friday at $72.76, extending a losing streak to seven consecutive sessions as the U.S. market heads into the first full trading week of 2026. The stock is down about 13% since Dec. 23 and roughly 29% below the record intraday high of $103 hit in early December. Shares traded between $72.15 and $77.82 on Friday, with about 854,000 shares changing hands. Investing The retreat follows a sharp run-up in early December after Kymera reported positive results from an early-stage patient study
4 January 2026
·····
Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus

Kymera Therapeutics (KYMR) stock drops 6.6% to start 2026 as insider sale filing stays in focus

NEW YORK, Jan 3, 2026, 20:43 ET — Market closed Kymera Therapeutics shares slid on Friday, ending down 6.6% at $72.76 as the biotech underperformed its sector even as the broader market started 2026 on a mixed note. The move matters because Kymera has been a high-beta biotech name since a sharp rally in December on early trial data for its KT-621 immunology program, leaving the stock sensitive to profit-taking and fresh supply from capital-raising activity. Kymeratx With U.S. markets facing a busy week of economic releases, risk appetite has been uneven and investors have leaned on near-term catalysts —
4 January 2026
····
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

NEW YORK, December 30, 2025, 14:30 ET — Regular session Shares of Kymera Therapeutics fell about 3% to $77.94 in afternoon trading on Tuesday, lagging a broader biotech dip. The SPDR S&P Biotech ETF was down about 1.4%, while the iShares Nasdaq Biotechnology ETF slipped about 1.1%. The pullback matters because Kymera has been one of the sector’s higher-volatility names this month, after a surge tied to new clinical data and a subsequent stock sale that increased its share count. With most of its next major readouts still far off, investors have been quick to reprice the stock around financing
30 December 2025
·····
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering and a wave of fresh analyst price‑target hikes.GlobeNewswire+3Investing.com+3Investing.com+3 This is the kind of setup that gets both momentum traders and long‑term biotech nerds leaning in. Where KYMR Stock Stands Today The immediate driver: KT‑621, Kymera’s oral STAT6 degrader, produced dupilumab‑like efficacy in atopic dermatitis (eczema) with clean safety in a small Phase 1b trial — and the Street went into
9 December 2025
·····

Stock Market Today

Carvana stock jumps 5% to $403.67 — here’s what CVNA traders are watching next

Carvana stock jumps 5% to $403.67 — here’s what CVNA traders are watching next

7 February 2026
Carvana shares rose 5.21% Friday to $403.67, rebounding after recent volatility sparked by a short-seller report from Gotham City Research. The company denied allegations of overstated earnings and undisclosed ties to DriveTime. Carvana will report Q4 and full-year 2025 results after markets close on Feb. 18. The January U.S. CPI report is scheduled for Feb. 13.
Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

Confluent stock hugs IBM’s $31 bid — here’s what investors watch next week

7 February 2026
Confluent shares closed at $30.57 Friday, 43 cents below IBM’s $31-per-share cash offer, ahead of key events next week. The company will report earnings Feb. 11 without a call or outlook, and shareholders vote on the merger Feb. 12. Confluent disclosed 17 demand letters and two lawsuits over proxy disclosures but denies wrongdoing. The IBM deal values Confluent at $11 billion.
Go toTop